Objective To investigate whether aligning exercise timing with chronotype enhances cardiometabolic and sleep-related benefits ...

BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant ...

Actively planning for HU6’s late-stage development in MASH - - HU6 is potential best-in-class oral MASH therapy designed to address unmet needs in MASH through a unique energy expenditure approach - ...

AstraZeneca’s pivotal phase III MIRANDA trial of tozorakimab to treat COPD meets primary endpoint: Cambridge, UK Positive high-level res ...

Third positive pivotal Phase III clinical trial of AstraZeneca’s IL-33-targeting biologic further demonstrates its benefits in COPD Positive high-level results from the pivotal Phase III MIRANDA trial ...

SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p<0.0001) from baseline at Week 12 in Robart’s ...

The trial will enrol around 180 adults with F2/F3 MASH.

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends ...

Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically ...

Povetacicept, a dual BAFF/APRIL inhibitor, significantly lowered proteinuria in patients with immunoglobulin A nephropathy ...

Consistent survival benefit observed across the poorest prognosis patient subgroups, including those with liver metastases and high disease burden 7-40X increases in tumor-infiltrating cytotoxic ...

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival -- Company intends to include these data in a future New Drug Application submission to the ...